{"protocolSection": {"identificationModule": {"nctId": "NCT00439738", "orgStudyIdInfo": {"id": "CVAH631BUS06"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults", "officialTitle": "A 16-week Double-blind, Randomized, Multicenter, Force-titration Study to Evaluate the Antihypertensive Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Therapy Compared to HCTZ Based Therapy in Obese, Hypertensive Patients"}, "statusModule": {"statusVerifiedDate": "2017-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-12"}, "primaryCompletionDateStruct": {"date": "2007-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-02-23", "studyFirstSubmitQcDate": "2007-02-23", "studyFirstPostDateStruct": {"date": "2007-02-26", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2008-11-05", "resultsFirstSubmitQcDate": "2009-02-09", "resultsFirstPostDateStruct": {"date": "2009-02-10", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-04-19", "lastUpdatePostDateStruct": {"date": "2017-05-16", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "External Affairs", "oldOrganization": "Novartis Pharmaceuticals"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The purpose of this study is to compare the blood pressure lowering efficacy of valsartan/hydrochlorothiazide (HCTZ) compared to hydrochlorothiazide for the treatment of obese hypertensive (mean sitting systolic blood pressure \\[MSSBP\\] \\>150 mmHg) patients."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Obesity, hypertension, valsartan/hydrochlorothiazide"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 412, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "valsartan/HCTZ", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Valsartan/HCTZ"]}, {"label": "HCTZ +Amlodipine", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: HCTZ + Amlodipine"]}], "interventions": [{"type": "DRUG", "name": "HCTZ + Amlodipine", "description": "* 12.5 mg HCTZ capsules\n* 25 mg HCTZ capsules\n* 5 mg amlodipine capsules\n* 10 mg amlodipine capsules", "armGroupLabels": ["HCTZ +Amlodipine"]}, {"type": "DRUG", "name": "Valsartan/HCTZ", "description": "* 160 mg film-coated valsartan tablets\n* 320 mg film-coated valsartan tablets\n* 12.5 mg HCTZ capsules\n* 25 mg HCTZ capsules", "armGroupLabels": ["valsartan/HCTZ"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Mean Sitting Systolic Blood Pressure (MSSBP)", "timeFrame": "Baseline to Week 8"}], "secondaryOutcomes": [{"measure": "Change in Mean Sitting Diastolic Blood Pressure (MSDBP)", "timeFrame": "Baseline to Weeks 4, 8, 12 and 16"}, {"measure": "Number of Patients Achieving Blood Pressure (BP) Control by Visit (< 140/90 mm Hg)", "description": "Mean sitting systolic blood pressure/mean sitting diastolic blood pressure \\< 140/90 mm Hg", "timeFrame": "Weeks 4, 8, 12 16 and End of Study (for patients that did not complete the last visit at week 16)"}, {"measure": "Number of Patients Achieving Blood Pressure (BP)Control by Visit (< 130/80 mm Hg)", "description": "Mean sitting systolic blood pressure/mean sitting diastolic blood pressure \\< 130/80 mm Hg", "timeFrame": "Week 4, 8, 12, 16, End of Study (for patients that did not complete the last visit at week 16)"}, {"measure": "Change From Baseline in Postprandial Glucose", "description": "After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test", "timeFrame": "Week 16"}, {"measure": "Change From Baseline in Postprandial Insulin", "description": "After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test", "timeFrame": "Week 16"}, {"measure": "Change From Baseline in Postprandial Non-esterified Fatty Acids", "description": "After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test", "timeFrame": "Week 16"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* 40 years of age or older\n* Moderate or severe high blood pressure defined as systolic blood pressure (the top number) greater than or equal to 150 mmHg and diastolic blood pressure (the bottom number) less then 110 mmHg\n* Central (abdominal) obesity\n\nExclusion Criteria:\n\n* Systolic blood pressure (the top number) greater than or equal to 180 mmHg and diastolic blood pressure (the bottom number) greater than or equal to 110 mmHg\n* Currently taking more then 3 medications to treat high blood pressure\n* Inability to stop all current blood pressure medications if any up to 4 weeks\n* History of Type 1 or Type 2 diabetes\n* History of stroke, mini-stroke (transient ischemic attack) or heart attack within the last 6 months\n* History of or current diagnosis of congestive heart failure\n* History of cancer within the past 5 years with the exception of localized basal cell carcinoma or squamous cell carcinoma\n* Women who are pregnant or nursing\n* Alcohol or drug abuse within the last 2 years\n\nOther protocol-defined inclusion/exclusion criteria may apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "40 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Terence T. Hart, MD", "city": "Muscle Shoals", "state": "Alabama", "zip": "35662", "country": "United States", "geoPoint": {"lat": 34.74481, "lon": -87.66753}}, {"facility": "Westlake Medical Research", "city": "Westlake Village", "state": "California", "zip": "91361", "country": "United States", "geoPoint": {"lat": 34.14584, "lon": -118.80565}}, {"facility": "Oklahoma Cardiovascular & Hypertension", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73132", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Northeast Tarrant Internal Medicine Assoc", "city": "Euless", "state": "Texas", "zip": "76040", "country": "United States", "geoPoint": {"lat": 32.83707, "lon": -97.08195}}, {"facility": "Frandsen Family Medicine", "city": "Port Orchard", "state": "Washington", "zip": "98366", "country": "United States", "geoPoint": {"lat": 47.54037, "lon": -122.63625}}]}, "referencesModule": {"references": [{"pmid": "22747613", "type": "DERIVED", "citation": "Deedwania PC, Zappe DH, Egan BM, Purkayastha D, Samuel R, Sowers JR. Does response of RAS blockade on serum K+ levels influence its glycemic-mitigating response when combined with hydrochlorothiazide? J Clin Hypertens (Greenwich). 2012 Jul;14(7):415-21. doi: 10.1111/j.1751-7176.2012.00635.x. Epub 2012 Apr 26."}, {"pmid": "22248871", "type": "DERIVED", "citation": "Ofili EO, Zappe DH, Purkayastha D, Samuel R, Sowers JR. Antihypertensive and metabolic effects of Angiotensin receptor blocker/diuretic combination therapy in obese, hypertensive African American and white patients. Am J Ther. 2013 Jan;20(1):2-12. doi: 10.1097/MJT.0b013e318230ae66."}, {"pmid": "20498618", "type": "DERIVED", "citation": "Sowers JR, Raij L, Jialal I, Egan BM, Ofili EO, Samuel R, Zappe DH, Purkayastha D, Deedwania PC. Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives. J Hypertens. 2010 Aug;28(8):1761-9. doi: 10.1097/HJH.0b013e32833af380."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Valsartan/HCTZ (Hydrochlorothiazide)"}, {"id": "FG001", "title": "HCTZ +Amlodipine"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "206"}, {"groupId": "FG001", "numSubjects": "206"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "170"}, {"groupId": "FG001", "numSubjects": "178"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "36"}, {"groupId": "FG001", "numSubjects": "28"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "13"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Abnormal Lab Values", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Valsartan/HCTZ (Hydrochlorothiazide)"}, {"id": "BG001", "title": "HCTZ +Amlodipine"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "206"}, {"groupId": "BG001", "value": "206"}, {"groupId": "BG002", "value": "412"}]}], "measures": [{"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "< 65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "172", "spread": "83.5"}, {"groupId": "BG001", "value": "180", "spread": "87.4"}, {"groupId": "BG002", "value": "352", "spread": "85.4"}]}]}, {"title": ">=65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "34", "spread": "16.5"}, {"groupId": "BG001", "value": "26", "spread": "12.6"}, {"groupId": "BG002", "value": "60", "spread": "14.6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "124"}, {"groupId": "BG001", "value": "148"}, {"groupId": "BG002", "value": "272"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "82"}, {"groupId": "BG001", "value": "58"}, {"groupId": "BG002", "value": "140"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Mean Sitting Systolic Blood Pressure (MSSBP)", "populationDescription": "Intent to Treat (ITT), Last Observation Carried Forward (LOCF)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to Week 8", "groups": [{"id": "OG000", "title": "Valsartan/HCTZ (Hydrochlorothiazide)"}, {"id": "OG001", "title": "HCTZ +Amlodipine"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "197"}, {"groupId": "OG001", "value": "204"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "159.7", "spread": "7.81"}, {"groupId": "OG001", "value": "159.0", "spread": "7.62"}]}]}, {"title": "Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "131.2", "spread": "16.26"}, {"groupId": "OG001", "value": "137.5", "spread": "13.52"}]}]}, {"title": "Change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-28.6", "spread": "15.61"}, {"groupId": "OG001", "value": "-21.5", "spread": "12.58"}]}]}]}, {"type": "SECONDARY", "title": "Change in Mean Sitting Diastolic Blood Pressure (MSDBP)", "populationDescription": "Intent to Treat (ITT), Last Observation Carried Forward (LOCF)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to Weeks 4, 8, 12 and 16", "groups": [{"id": "OG000", "title": "Valsartan/HCTZ (Hydrochlorothiazide)"}, {"id": "OG001", "title": "HCTZ +Amlodipine"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "197"}, {"groupId": "OG001", "value": "204"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "94.9", "spread": "7.94"}, {"groupId": "OG001", "value": "93.6", "spread": "8.18"}]}]}, {"title": "Week 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "85.7", "spread": "9.38"}, {"groupId": "OG001", "value": "87.6", "spread": "9.20"}]}]}, {"title": "Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "81.9", "spread": "9.87"}, {"groupId": "OG001", "value": "85.1", "spread": "8.54"}]}]}, {"title": "Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "81.1", "spread": "9.14"}, {"groupId": "OG001", "value": "82.8", "spread": "8.75"}]}]}, {"title": "Week 16", "categories": [{"measurements": [{"groupId": "OG000", "value": "80.8", "spread": "10.14"}, {"groupId": "OG001", "value": "80.9", "spread": "8.66"}]}]}, {"title": "Change from baseline to week 16", "categories": [{"measurements": [{"groupId": "OG000", "value": "-14.0", "spread": "9.90"}, {"groupId": "OG001", "value": "-12.7", "spread": "8.35"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients Achieving Blood Pressure (BP) Control by Visit (< 140/90 mm Hg)", "description": "Mean sitting systolic blood pressure/mean sitting diastolic blood pressure \\< 140/90 mm Hg", "populationDescription": "Intent to Treat (ITT)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Weeks 4, 8, 12 16 and End of Study (for patients that did not complete the last visit at week 16)", "groups": [{"id": "OG000", "title": "Valsartan/HCTZ (Hydrochlorothiazide)"}, {"id": "OG001", "title": "HCTZ +Amlodipine"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "197"}, {"groupId": "OG001", "value": "204"}]}], "classes": [{"title": "Week 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "91"}, {"groupId": "OG001", "value": "69"}]}]}, {"title": "Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "123"}, {"groupId": "OG001", "value": "102"}]}]}, {"title": "Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "112"}]}]}, {"title": "Week 16", "categories": [{"measurements": [{"groupId": "OG000", "value": "124"}, {"groupId": "OG001", "value": "140"}]}]}, {"title": "End of study", "categories": [{"measurements": [{"groupId": "OG000", "value": "133"}, {"groupId": "OG001", "value": "146"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients Achieving Blood Pressure (BP)Control by Visit (< 130/80 mm Hg)", "description": "Mean sitting systolic blood pressure/mean sitting diastolic blood pressure \\< 130/80 mm Hg", "populationDescription": "Intent to Treat (ITT)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 4, 8, 12, 16, End of Study (for patients that did not complete the last visit at week 16)", "groups": [{"id": "OG000", "title": "Valsartan/HCTZ (Hydrochlorothiazide)"}, {"id": "OG001", "title": "HCTZ +Amlodipine"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "197"}, {"groupId": "OG001", "value": "204"}]}], "classes": [{"title": "Week 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "18"}]}]}, {"title": "Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "23"}]}]}, {"title": "Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "46"}]}]}, {"title": "Week 16", "categories": [{"measurements": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "65"}]}]}, {"title": "End of Study", "categories": [{"measurements": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "68"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Postprandial Glucose", "description": "After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test", "populationDescription": "Only those patients who completed the study through week 16 were included in this analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Week 16", "groups": [{"id": "OG000", "title": "Valsartan/HCTZ (Hydrochlorothiazide)"}, {"id": "OG001", "title": "HCTZ +Amlodipine"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "197"}, {"groupId": "OG001", "value": "204"}]}], "classes": [{"title": "Baseline visit (0 minutes)", "categories": [{"measurements": [{"groupId": "OG000", "value": "98.0", "spread": "15.91"}, {"groupId": "OG001", "value": "99.4", "spread": "19.12"}]}]}, {"title": "Week 16 (0 minutes)", "categories": [{"measurements": [{"groupId": "OG000", "value": "98.1", "spread": "15.68"}, {"groupId": "OG001", "value": "102.8", "spread": "17.81"}]}]}, {"title": "Change from baseline to week 16 (0 minutes)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.5", "spread": "13.71"}, {"groupId": "OG001", "value": "3.4", "spread": "18.28"}]}]}, {"title": "Baseline visit (120 minutes)", "categories": [{"measurements": [{"groupId": "OG000", "value": "123.9", "spread": "47.18"}, {"groupId": "OG001", "value": "127.7", "spread": "40.30"}]}]}, {"title": "Week 16 (120 minutes)", "categories": [{"measurements": [{"groupId": "OG000", "value": "126.3", "spread": "49.52"}, {"groupId": "OG001", "value": "146.5", "spread": "56.51"}]}]}, {"title": "Change from baseline to week 16 (120 minutes)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.1", "spread": "38.21"}, {"groupId": "OG001", "value": "18.9", "spread": "40.88"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Postprandial Insulin", "description": "After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test", "populationDescription": "Only those patients who completed the study through week 16 were included in this analysis", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Week 16", "groups": [{"id": "OG000", "title": "Valsartan/HCTZ (Hydrochlorothiazide)"}, {"id": "OG001", "title": "HCTZ +Amlodipine"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "197"}, {"groupId": "OG001", "value": "204"}]}], "classes": [{"title": "Baseline visit (0 minutes)", "categories": [{"measurements": [{"groupId": "OG000", "value": "19.66", "spread": "20.435"}, {"groupId": "OG001", "value": "20.37", "spread": "20.583"}]}]}, {"title": "Week 16 (0 minutes)", "categories": [{"measurements": [{"groupId": "OG000", "value": "23.45", "spread": "26.039"}, {"groupId": "OG001", "value": "23.62", "spread": "19.267"}]}]}, {"title": "Change from baseline to week 16 (0 minutes)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.41", "spread": "28.427"}, {"groupId": "OG001", "value": "3.67", "spread": "19.170"}]}]}, {"title": "Baseline visit (120 minutes)", "categories": [{"measurements": [{"groupId": "OG000", "value": "92.04", "spread": "82.183"}, {"groupId": "OG001", "value": "95.95", "spread": "76.483"}]}]}, {"title": "Week 16 (120 minutes)", "categories": [{"measurements": [{"groupId": "OG000", "value": "116.04", "spread": "129.880"}, {"groupId": "OG001", "value": "120.01", "spread": "100.302"}]}]}, {"title": "Change from baseline to week 16 (120 minute)", "categories": [{"measurements": [{"groupId": "OG000", "value": "24.68", "spread": "90.094"}, {"groupId": "OG001", "value": "28.07", "spread": "71.674"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Postprandial Non-esterified Fatty Acids", "description": "After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test", "populationDescription": "Only those patients who completed the study through week 16 were included in this analysis", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Week 16", "groups": [{"id": "OG000", "title": "Valsartan/HCTZ (Hydrochlorothiazide)"}, {"id": "OG001", "title": "HCTZ +Amlodipine"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "197"}, {"groupId": "OG001", "value": "204"}]}], "classes": [{"title": "Baseline visit (0 minutes)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.45", "spread": "0.208"}, {"groupId": "OG001", "value": "0.47", "spread": "0.318"}]}]}, {"title": "Week 16 (0 minutes)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.46", "spread": "0.194"}, {"groupId": "OG001", "value": "0.47", "spread": "0.196"}]}]}, {"title": "Change from baseline to week 16 (0 minutes)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.01", "spread": "0.249"}, {"groupId": "OG001", "value": "0.00", "spread": "0.341"}]}]}, {"title": "Baseline visit (120 minutes)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.11", "spread": "0.090"}, {"groupId": "OG001", "value": "0.10", "spread": "0.116"}]}]}, {"title": "Week 16 (120 minutes)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.10", "spread": "0.093"}, {"groupId": "OG001", "value": "0.10", "spread": "0.056"}]}]}, {"title": "Change from baseline to week 16 (120 minutes)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.01", "spread": "0.117"}, {"groupId": "OG001", "value": "-0.01", "spread": "0.120"}]}]}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "1-862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M12701", "name": "Obesity", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000068756", "term": "Valsartan"}, {"id": "D000006852", "term": "Hydrochlorothiazide"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M301", "name": "Valsartan", "asFound": "Extended", "relevance": "HIGH"}, {"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "CRC", "relevance": "HIGH"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}